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Mortality and morbidity remain high in pediatric lower respiratory tract infections (LRTIs) 
despite progress in research and implementation of global diagnostic and treatment 
strategies in the last decade. Still, 120 million annual episodes of pneumonia affect 
children younger than 5 years each year leading to 1.3 million fatalities with the major 
burden of disease carried by low- and middle-income countries (95%). The definition of 
pneumonia is still challenging. Traditional diagnostic measures (i.e., chest radiographs, 
C-reactive protein) are unable to distinguish viral and from bacterial etiology. As a result, 
common antibiotic overuse contributes to growing antibiotic resistance. We present an 
overview of current evidence from observational and randomized controlled trials on 
a procalcitonin (PCT)-based diagnosis of pediatric LRTIs and discuss the need for an 
adequate PCT threshold for antibiotic treatment decision-making.
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MOrBiDitY AND MOrtALitY OF LOWer resPirAtOrY  
trAct iNFectiONs (Lrtis) iN cHiLDreN
Community-acquired pneumonia (CAP) remains a leading cause of childhood morbidity and 
mortality worldwide. About 120 million episodes of pneumonia are estimated to affect children 
younger than 5  years each year with as many as 14 million episodes being severe enough to 
require hospital admission and 1.3 million episodes leading to death (1–3). CAP affects children 
younger than 2 years most frequently and most severely (2, 4). The majority of pediatric cases 
(95%) occur in low- and middle-income countries (e.g., incidence in Africa 0.27 episodes per 
child-year) with 80% of CAP fatalities occurring in south-east Asia and Africa (2). In contrast, 
the incidence in high-income countries is much lower. For example, Europe has a pneumonia 
incidence of 0.03 per child-year with 1.4% of the global mortality. However, pediatric respiratory 
tract infections still represent a significant part of each country’s childhood morbidity in both the 
developing and the developed world: in Nigeria, 44% of pediatric hospital admissions are due to 
LRTIs (5), whereas in continental Europe, 9% of admitted children present LRTI (6). Non-fatal 
morbidity and pneumonia severity are driven by complications including pleural effusions (from 1 
to 16% of pediatric pneumonia cases admitted to EDs) (7–9), empyema (4%) (8), and necrotizing 
pneumonia (0.8%) (10).
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DiAGNOstic DiLeMMA AND ANtiBiOtic 
OverUse
Reliable differentiation between uncomplicated and self-limit-
ing acute respiratory tract infections and more severe disease 
requiring antibiotic treatment remains challenging. Bacterial 
pneumonia in need of antibiotic treatment may complicate viral 
respiratory tract infection. However, the presence of bacteria in 
the respiratory tract may not require antibiotic treatment as the 
colonization of the upper respiratory tract does not necessarily 
lead to pneumonia and as an immunocompetent patient may 
clear the bacteria without antibiotic treatment. Therefore, the 
physician faces suboptimal diagnostic tools to make informed 
treatment decisions. The difficulty in diagnosing LRTIs in 
need of antibiotic treatment in a pediatric patient is based on 
two major issues. First, causative etiology is highly variable, 
and mixed viral–bacterial infections can occur in 30–90% of 
pneumonia cases in children (11–14). Blood culture results are 
not available immediately and rarely positive in the outpatient 
(<2%) (15), and organisms identified from nasopharyngeal 
swabs may only reflect colonization. Better correlation can be 
expected from endotracheal aspirates, but this stays reserved 
for ventilated intensive care patients or patients undergoing 
bronchial lavage. Second, biomarkers of inflammation and 
radiologic imaging have not been reliable so far in differen-
tiating viral from bacterial infections and are not available in 
every medical setting. Therefore, only non-specific clinical 
parameters (tachypnea, chest indrawing in mild and moderate 
cases, reduced fluid uptake, and/or reduced consciousness in 
very severe cases) with questionable ability to distinguish viral 
from bacterial LRTI, and no diagnostic tests are included in the 
WHO definition of childhood pneumonia and in the British 
Thoracic Society guidelines for the management of uncompli-
cated pediatric pneumonia (16, 17). However, clinical param-
eters remain an important element of diagnosis and assessment 
of disease severity in every medical setting, including low- and 
medium-income countries.
Diagnostic shortcomings, lack of time, and physician’s 
uncertainty in the light of potential life-threatening complica-
tions seem to trigger antibiotic prescribing for pediatric child-
hood infections, and many prescriptions are made “just in case” 
(18, 19). The resulting antibiotic overtreatment of pediatric 
chest infections (20, 21) has to be seen critically in the light 
of increasing antibiotic consumption and resistance rates (22).
DiAGNOstic UNcertAiNtY OF 
LABOrAtOrY AND rADiOLOGicAL 
tests
With the intention to avoid undertreatment or overtreatment 
of LRTI, acute phase reactants [e.g., C-reactive protein (CRP), 
white blood cell count], and radiographic tests are widely used 
for daily decision-making on antibiotic treatment, despite their 
known limitations. In a meta-analysis including 8 studies and 
1,230 patients, only a relatively weak cumulative positive predic-
tive value of 64% could be calculated for a serum CRP exceeding 
40–60  mg/L (23). Korppi showed a specificity of 82% and a 
sensitivity of 34% for the combination of white blood cell count, 
CRP, procalcitonin (PCT), and erythrocyte sedimentation rate 
for the prediction of alveolar infiltrates on chest radiographs 
(24). A number of further studies aimed at increasing the predic-
tive performance by combining various laboratory parameters, 
but no combination truly succeeded in the development of a 
convincing algorithm for differentiating CAP in need of antibi-
otic treatment from other febrile LRTI (11, 25–27). CRP-guided 
antibiotic treatment has not been tested against standard care 
in children so far. However, a recent meta-analysis for adults 
with acute respiratory tract infections demonstrated a moder-
ate reduction of antibiotic prescribing when CRP was included 
in treatment decision-making [relative risk (RR) 0.7, 95% CI 
0.60–0.90] (28). Further, chest radiographs are not reliable and 
therefore not recommended in non-complicated febrile LRTI, 
as numerous studies have shown high intrarater and interrater 
variabilities. A strikingly low interrater agreement of only 9% in 
non-alveolar pneumonia could be shown by Ben Shimol et al., 
even when standardized radiologic WHO criteria were used by 
all raters (29, 30).
PrOcALcitONiN
The shortcomings of traditional diagnostic measures have 
driven studies investigating PCT as a biomarker. PCT is a 
precursor peptide of calcitonin and is released as a part of the 
pro-inflammatory response of the innate immune system from 
parenchymal cells reaching detectable levels within 4  h after 
endotoxin stimulation, i.e., much earlier than CRP (31). High 
PCT (usually >2  ng/mL) seems to be good marker for blood 
culture-positive pneumococcal infection in CAP. Decrease of 
PCT with amoxicillin treatment is usually rapid, and persistence 
of high PCT levels is generally due to a pneumococcal pleural 
focus that antibiotics cannot reach (32–34). It was shown that 
moderately elevated PCT (1–2.5 ng/mL) could be found in CAP 
with positive blood culture for Streptococcus pneumoniae mainly 
in bacterial superinfection after an initial viral episode, possibly 
reflecting transitory immune impairment (33). Further, PCT has 
been shown to strongly correlate with sepsis and septic shock in 
neutropenic (35, 36) and immune-competent patients (32, 37). 
PCT is particularly good in differentiating bacterial from viral 
meningitis in children (38) and seems to be useful to rule-in 
pyelonephritis, but studies on urinary tract infections display a 
high heterogeneity, which is why PCT cannot be recommended 
for antibiotic management of urinary tract infections at this 
point. PCT seems to be a useful marker for reduction of the anti-
biotic use in adult and neonatal intensive care patients (39–42), 
whereas data available for pediatric patients in intensive care 
are rather inconclusive so far and is not based on randomized 
controlled trials (RCTs) (43).
Pct-GUiDeD rcts iN ADULts
The first available retrospective and observational data on adult 
CAP motivated Christ-Crain et al. (44) to design a RCT testing 
PCT guidance in adult patients with all kinds of LRTI presenting 
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to the emergency room. The authors used the available evidence 
at this point of time for the first definition of PCT treatment 
thresholds. Previous studies on chronic obstructive pulmonary 
disease and sepsis had shown that the presence of bacterial 
infections was highly unlikely with PCT values <0.1  ng/mL 
and likely with PCT  ≥  0.5  ng/mL, but an exact treatment 
threshold was unknown. Therefore, the authors implemented 
an interventional PCT treatment algorithm incorporating 
the increasing risk of bacterial infection with increasing PCT 
values: PCT <  0.1  ng/mL: bacterial infection highly unlikely 
and antibiotic treatment strongly discouraged, PCT < 0.25 ng/
mL: bacterial infection unlikely and antibiotic treatment rather 
discouraged, PCT ≥ 0.25 ng/mL: bacterial infection possible and 
start of antibiotic treatment advised, PCT ≥ 0.5 ng/mL: bacterial 
infection suggestive and antibiotic treatment strongly advised. 
The control group was treated according to international guide-
lines. Reassessment was possible after 6–24  h. The PCT guid-
ance resulted in a significant lower antibiotic prescription rate 
(RR 0.49, 95% CI 0.44–0.55, p < 0.0001) without compromising 
patients’ safety outcome (44).
Following this informative finding, in a second interven-
tional trial with identical PCT guidance for CAP, Christ-Crain 
et al. (45) proved PCT to be useful not only for the reduction of 
antibiotic prescribing but also for shortening antibiotic expo-
sure by the reassessment of patients on 4, 6, and 8 days following 
enrollment. Antibiotic exposure was significantly shortened 
by 55% (p  <  0.001) in the PCT-guided group with similar 
patients’ safety outcome in both the intervention and the control 
groups (45).
The promising results of these first interventional studies 
were confirmed later in a large multicenter RCT involving 
1,359 adult patients presenting to the EDs with any LRTI, 
in which the intervention group was treated with antibiotics 
according to the same PCT guidance algorithm and the control 
group was treated according to the international guidelines. 
The mean duration of antibiotic exposure was significantly 
shorter (5.7 vs. 8.7  days; relative change −34.8%; 95% CI 
−40.3% to −28.7%), and the antibiotic prescription rates of all 
LRTI were significantly lower (75.4 vs. 87.7%; −12.2%; −16.3 
to −8.1%) in the intervention group without adverse effect on 
patients’ outcome (46).
Pct-GUiDeD rcts iN cHiLDreN AND 
ADOLesceNts
The success of PCT guidance in adults with LRTI also triggered 
pediatric research in this field. Following observational trials in 
children with promising results (32, 33, 47, 48), two RCTs have 
been published until to date in the English language. Esposito 
et al. published the first RCT in hospitalized children (>1 month 
and <14  years of age) with pneumonia in 2011. Diagnosis 
of pneumonia was made based on clinical findings (fever or 
cough, tachypnea, dyspnea or respiratory distress, and breath-
ing with grunting or wheezing with rales) and confirmed by 
chest radiography (infiltration or consolidation). Patients with 
pleural effusions, empyema, lung necrosis and pneumatocele, 
underlying chronic disease, malnutrition, and patients under 
antibiotic treatment were excluded. Patients were randomized 
according to the adult interventional studies and were allocated 
to PCT-guided antibiotic treatment or to treatment accord-
ing to international guidelines. In the intervention group, 
children did not receive antibiotic treatment, if PCT values 
were <0.25  ng/mL and were treated with antibiotics, if PCT 
values were ≥0.25  ng/mL. PCT was measured every 2  days 
until hospital discharge. Three hundred and ten children were 
enrolled on hospitalization, and after hospital discharge, all 
children were reassessed at 14 (SD 2) and 28 (3) days following 
randomization. Fourteen percent of CAP cases in the interven-
tion group did not have to be treated according to constant low 
PCT values, whereas all patients in the control group received 
antibiotic treatment. Most of PCT-guided patients had their 
antibiotic treatment stopped on day 6 (37.4%) or 8 (46.6%). 
All antibiotic treatment was stopped according to PCT guid-
ance latest on day 10. In contrast, most antibiotic treatment 
periods in the control group lasted until day 10 (82.6%) with 
some treatment periods extended until day 12 (25.2%) or day 
14 (13.5%). In line with the adult data, this trial demonstrated 
a significant reduction of both antibiotic treatment rate (85.8 
vs. 100%, p < 0.05) and duration (5.4 vs. 11.0 days, p < 0.05) 
by PCT-guided treatment without compromising patients’ 
outcome: rates of disease relapse and secondary antibiotic 
prescriptions were similar in the intervention and the control 
groups. Further, antibiotic-related adverse events were lower in 
the PCT group (4 vs. 25%, p < 0.05) (49). This first RCT for PCT 
guidance in pediatric LRTI is very valuable for pediatricians 
and clinical researchers, because it showed for the first time 
the feasibility of PCT guidance in pediatric patients, using the 
PCT treatment threshold 0.25 ng/mL adopted from adult stud-
ies. Further, a moderate, but significant reduction of antibiotic 
treatment could be achieved. The trial is limited by including 
only uncomplicated hospitalized pneumonia cases, which were 
diagnosed by chest radiograph. Further, with complications 
excluded, safety assessment in severe and complicated cases 
was limited as also correctly stated by the authors.
In 2013, the authors of the present study published the 
second RCT involving 337 children and adolescents with any 
LRTI presenting to the pediatric ED of two tertiary care centers 
(50). Exclusion criteria were severe immune depression, immu-
nosuppressive treatment, neutropenia, cystic fibrosis, acute 
laryngotracheitis, and hospital stay within previous 14  days. 
The treatment algorithm in the interventional PCT-guided 
group was the same as in the previous adult studies. It increas-
ingly encouraged antibiotic treatment according to increasing 
PCT values: strongly discouraged (<0.1  mg/L), discouraged 
(0.1–0.25 ng/mL), encouraged (0.26–0.5 ng/mL), and strongly 
encouraged (>0.5 ng/mL). Patients and laboratory values were 
reassessed routinely on day 3 and 5 after enrollment and pos-
sibly earlier if patients appeared severely sick. On the last day 
of assessment (day 5), further antibiotic treatment duration 
was determined also according to PCT values: >1  ng/mL: 
7  days, 0.51–1  ng/mL: 5  days, 0.26–0.5  ng/mL: 3  days, and 
<0.25  ng/mL: no antibiotic. The study did not demonstrate 
an overall reduced antibiotic prescription rate: PCT group 
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62% vs. control group 56%, p =  0.36. PCT guidance treated 
significantly more patients in the non-CAP subgroup (45% 
vs. 17%, p = 0.002), whereas in CAP, there was no difference 
(71% vs. 79%, p = 0.25). However, the duration of antibiotic 
exposure was reduced in the PCT-guided group in all LRTI 
cases (duration 4.5 vs. 6.3  days, p =  0.039) and in the CAP 
subgroup (5.7 vs. 9.1 days, respectively, p = 0.001). In contrast, 
in the subgroup of non-CAP LRTI, antibiotic treatment was 
significantly prolonged with PCT guidance (2.4 vs. 1.6  days, 
p =  0.01) (50). Patients’ safety outcome was not affected by 
PCT guidance: 23% in the PCT-guided group and 20% in the 
control group showed serious adverse events, complications 
of LRTI, or disease-specific failure (odds ratio 1.16, 95% CI 
0.69–1.97). The most important result of this trial was the fea-
sibility and safety confirmation of PCT guidance in pediatric 
LRTI cases, because in the PCT-guided intervention group, all 
antibiotic treatment decisions were based solely on PCT levels 
irrespective of clinical, laboratory, or radiographic findings. 
The drawbacks of PCT guidance were the failure to reduce 
antibiotic prescription in all LRTI, the higher treatment rate, 
and longer treatment duration in non-CAP LRTI. A potential 
explanation for this might be that the PCT treatment threshold 
previously tested in adults (0.25 ng/mL) was too low for the 
pediatric population. A sub-analysis of this study (Baumann 
et  al., unpublished) demonstrated the PCT distribution in 
different radiologically diagnosed subgroups: non-CAP LRTI 
[n =  118, PCT median 0.2 ng/mL, interquartile range (IQR) 
0.1–0.4], CAP (n =  154, 0.8, 0.2–5.3), and lobar pneumonia 
(n = 33, 8.0, 1.9–20.6), p < 0.05. On the basis of these results, 
we speculate that the adoption of the adult treatment threshold 
of 0.25 ng/mL was not adequate for children and that higher 
PCT treatment thresholds of possibly 0.5 or 1  ng/mL might 
be more appropriate. Median PCT levels in children and ado-
lescents with any LRTI in this study were slightly higher than 
observed in the largest adult RCT [median: 0.28 ng/mL (IQR 
0.14–2.17) vs. 0.24 (0.11–1.36)]. This may further suggest that, 
in general, children develop higher levels of PCT in response to 
inflammatory stimuli compared to adults. This is supported by 
a retrospective study published by Cohen et al. in 2012 inves-
tigating the performance of different PCT levels in predicting 
clinical responses to beta-lactam treatment in febrile pediatric 
CAP (34). A rapid response with apyrexia within 48 h as a proxy 
for pneumococcal infection was predicted with best accuracy 
by a high PCT ≥ 3 ng/mL. Children with a rapid response to 
antibiotic treatment, and therefore likeliness of pneumococcal 
infection, revealed significantly higher PCT levels than the 
ones with delayed response (i.e., >48  h) [median (IQR) 3.7 
(1–9.4) vs. 0.7 (0.2–2.9), p = 0.002] (34).
Despite these first positive results, there are still limitations 
to PCT use. It has been shown than some few patients do not 
reveal high PCT values in case of local infection with negative 
blood culture or in severe systemic infections (51). Further, PCT 
might be elevated in case of viral or Mycoplasma pneumoniae 
infection (33, 52). It is likely that future studies evaluating higher 
PCT thresholds in pediatric respiratory tract infections may 
be able to show antibiotic-sparing effects, but may also reveal 
a decrease in negative predictive value. Further, a PCT higher 
than 1 or 2 ng/mL in suspected viral respiratory tract infection 
might be caused by bacterial superinfection. Thus, PCT use for 
antibiotic treatment decision-making in pediatric LRTI cannot 
replace, but serve as a useful element of comprehensive clinical 
decision-making.
An increasingly interesting role play modern rapid diagnostic 
tests such as multiplex polymerase chain reaction (mPCR). 
A recent retrospective cohort study with 4,779 hospitalized pedi-
atric patients showed a reduction of antibiotic treatment duration 
when patients managed with mPCR were compared to a historic 
cohort, in which mPCR has not been used (median 4 vs. 5 days, 
p < 0.01). This held true even though the mPCR group appeared 
to be more severely sick, and patients from that group were 
admitted to the intensive care unit more often (53). Quantitative 
real-time PCR of S. pneumoniae load in nasopharyngeal secre-
tions in combination with rapid immunofluorescence testing for 
viruses in suspected mixed viral–bacterial LRTIs have the poten-
tial to further facilitate the diagnosis of bacterial CAP (54) and 
the determination of antibiotic treatment need, when they are 
integrated in treatment decision models alongside with clinical 
and laboratory parameters.
cONcLUsiON
Over the past 15 years, pediatric evidence emerged for PCT as a 
useful diagnostic component for antibiotic treatment decisions 
in febrile LRTI and for other infectious diseases such as sepsis, 
meningitis, and urinary tract infections. Feasibility and safety of 
PCT antibiotic guidance were proven for adult thresholds used 
in children and adolescents with LRTIs irrespective of other 
diagnostic tests. Still, the number of pediatric studies and par-
ticipants is limited, and the treatment threshold for pediatric use 
remains to be confirmed. The currently published low treatment 
thresholds for pediatric LRTI may be an important reason for 
the moderate effect of PCT guidance on antibiotic sparing so far. 
Based on the available literature to date, large high-quality studies 
testing higher PCT treatment thresholds and possibly novel point 
of care tests would be informative. The integration of rapid viral 
immunofluorescence tests and bacterial real-time mPCR could 
further help to individualize antibiotic treatment of pediatric 
LRTI. PCT can be a useful component of a comprehensive clinical 
assessment and supports treatment decisions in pediatric LRTI.
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